Teva to Defend Ruling Allowing Narcan Generic at Federal Circuit

July 27, 2021, 8:29 PM

Adapt Pharma Inc.'s four patents on Narcan spray for treating opioid overdoses were properly invalidated because their components had been widely used for decades, Teva Pharmaceuticals USA Inc. will tell the Federal Circuit at oral argument.

The ruling from the U.S. District Court for the District of New Jersey paved the way for drug companies like Teva to make generic versions of Narcan. A three-judge panel of the U.S. Court of Appeals for the Federal Circuit will consider Adapt’s appeal Monday.

Adapt argues the trial court misapplied rules the Federal Circuit has laid out to avoid the risk that “once ...

To read the full article log in. To learn more about a subscription click here.